Excipients play a major role in the development of tablets and capsules for the health science industry. As active pharmaceutical ingredients (API), and manufacturing processes evolve, the need for excipients with greater flexibility increases.
More than 20 years ago, JRS PHARMA developed a new and innovative excipient PROSOLV SMCC to alleviate some of the known deficiencies of conventional binders including low-bulk density, poor flow, loss of compatability, stickiness issues, and sensitivity to lubricants.
PROSOLV SMCC addresses these challenges and offers enhanced performance.
To find out more, download this free whitepaper.